( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

 ISSN 2394-3211

Impact Factor: 7.065

 ICV - 79.57



*Giyasova Masuda Giyasovna, Shamsutdinova Maksuda Ilyasovna, Yunusov Asrorjon Abdullayevich, Elamanova Vazira Ruyddinova, Akhmedov Sherzod Adkhamovich and Sobitkhodzhaeva Saida Ulmasovna


In order to conduct a comparative assessment of the effect of anticoagulant therapy on the coagulation profile and the outcome of coronavirus infection (COVID-19), were examined 372 patients with laboratory-confirmed COVID-19 (moderate-to-severe) in the Specialized Hospital from August to December 2020. The ratio of men and women was 1.6 / 1; the average age was 57.4 ± 6.77 years. In the course of the study, the antithrombotic and hemorrhagic effects of the oral anticoagulant Rivaroksaban Nobel (n = 122) in comparison with the parenteral anticoagulant Enoxaparin sodium (Clexane) (n = 250) were evaluated in a comparative aspect. Based on the risk of venous thromboembolism, standard treatment doses were used for oral Rivaroksaban Nobel 20 mg / day and Enoxaparin sodium (Clexane) is 8,000 IU (80 mg) once daily by subcutaneous (SC) injection. The study found that the incidence of both thromboembolic outcomes and bleeding events did not show statistically significant differences between the clinical and laboratory parameters of patients with COVID-19 with the recommended anticoagulant therapy Rivaroksaban NOBEL, compared with Enoxaparin sodium (Clexane). However, Enoxaparin sodium (Clexane) has shown more significant clinical efficacy compared to Rivaroksaban Nobel. On the other hand, during the use of Rivaroksaban Nobel, there were no significant differences in the incidence of acute respiratory distress syndrome and deaths compared with Enoxaparin sodium (Clexane). Thus, our study confirms the hypothesis about the safety and efficacy of the oral anticoagulant Rivaroksaban Nobel for the prevention of venous thromboembolism in hospitalized patients with moderate to severe COVID-19.

Keywords: Coronavirus infection (COVID-19), coagulation profile, anti-coagulant therapy, direct oral anticoagulants, unfractionated heparin, low-molecular-weight heparins, rivaroksaban, enoxaparin.

[Full Text Article] [Download Certificate]


  All Since 2019
 Citation  3086  2560
 h-index  18  17
 i10-index  64  44



  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 May 2024 Issue has been Published, Kindly check it on


    MAY 2024 issue has been successfully launched on MAY 2024.

  • EJPMR New Impact Factor

    EJPMR Impact Factor has been Increased to 7.065 for Year 2024.

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database Academia